Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Bempedoic Acid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 919Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MILOS Study Highlights Bempedoic Acid's Potential In Dyslipidemia
    MILOS Study Highlights Bempedoic Acid's Potential In Dyslipidemia

    11 Oct 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/milos-study-highlights-potential-of-bempedoic-acid-to-advance-dyslipidemia-treatment-globaldata/

    EXPRESSPHARMA
    11 Oct 2024
    Share Share
    MILOS German Cohort Results Show Increase In LDL-C Goal With
    MILOS German Cohort Results Show Increase In LDL-C Goal With

    27 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240926678909/en

    BUSINESSWIRE
    27 Sep 2024
    Share Share
    Bempedoic Acid Cut CVD Risk Across Patient Groups Per CLEAR Outcomes
    Bempedoic Acid Cut CVD Risk Across Patient Groups Per CLEAR Outcomes

    29 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240523300818/en

    BUSINESSWIRE
    29 May 2024
    Share Share
    NILEMDO, NUSTENDI Approved In EU For Cholesterol Lowering
    NILEMDO, NUSTENDI Approved In EU For Cholesterol Lowering

    22 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240514593487/en

    BUSINESSWIRE
    22 May 2024
    Share Share
    FDA Confirms Para IV Patent Litigation for Bempedoic Acid (Nexlizet) Tablets
    FDA Confirms Para IV Patent Litigation for Bempedoic Acid (Nexlizet) Tablets

    26 Apr 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-bempedoic-acid-nexlizet-tablets-6743.pdf

    FDA
    26 Apr 2024
    Share Share
    FDA Confirms Para IV Patent Litigation for Bempedoic Acid (Nexletol) Tablets
    FDA Confirms Para IV Patent Litigation for Bempedoic Acid (Nexletol) Tablets

    26 Apr 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-bempedoic-acid-nexletol-tablets-12306.pdf

    FDA
    26 Apr 2024
    Share Share